J&J's OTC climbs but consent decree continues

16 October 2015 - Deborah Wilkes

Archived

Johnson & Johnson's OTC sales in the US increased by 22.4% to US$383 million in the third quarter of 2015, as the company reintroduced Tylenol Arthritis. However, the company said its McNeil Consumer Healthcare subsidiary would continue to operate under a consent decree for a further five years.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: